Category Archives: Clinical Cardiology

Data presented provides additional insight into potential mechanisms by which VASCEPA lowers cardiovascular risk DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. Continue reading →

Dr Carly Schott, market manager, cardiology and critical care, Roche Diagnostics UK & Ireland writes about how COVID-19 is a ticking time bomb for heart failure patients, and how improved of existing tools can save lives. Heart failure affects almost one million people in the UK. Although it is described as a modern-day epidemic, with worse survival rates than breast, prostate and bladder cancer, it is not prioritised in the same way as other diseases Continue reading →

Newswise TORONTO (October 9, 2020) One in five Canadian adults is currently living with arthritis, a disease causing inflammation of the joints, which can result in chronic, debilitating pain, reduced mobility and premature disability. Continue reading →

October 09, 2020 02:00 ET | Source: Saniona AB multilang-release PRESS RELEASE October 9, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it received written feedback from the U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO). Continue reading →

October 09, 2020 09:25 ET | Source: Merit Medical Systems, Inc. SOUTH JORDAN, Utah, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc Continue reading →

Heart health was top of mind on World Heart Day, marked on September 29 2020. Those with underlying heart conditions are at significantly higher risk of Covid-19, which is why awareness around heart health is arguably more important than ever Continue reading →

A state-of-the-art review released today aims to explore the overlaps between influenza and COVID-19, their implications for cardiovascular disease, and strategies for vaccine development. Continue reading →

Early initiation of rhythm control therapy was found to reduce cardiovascular outcomes in patients with newly diagnosed atrial fibrillation (AF) and cardiovascular conditions, according to the primary results of a clinical trial presented at the European Society of Cardiology Congress 2020, held virtually August 29 to September 1 and published in the New England Journal of Medicine.1,2 The results of the multi-center, prospective, randomized, open, blinded-outcome assessment Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST AFNET 4; ClinicalTrials.gov Identifier: NCT01288352) were presented by Paulus Kirchhof, MD, professor of cardiovascular medicine at the University Heart and Vascular Center at UKE Hamburg and first author on this study. An estimated 5% of patients with AF even when adequately managed are thought to experience serious cardiovascular events that include stroke, heart failure, acute coronary syndrome, and cardiovascular death. Antiarrhythmic drugs which, along with AF ablation are safe approaches for patients with AF and concomitant cardiovascular conditions were not found to be superior to rate control strategies in achieving rhythm control in patients with established AF in previous clinical trials. Continue reading →

Amid the COVID-19 pandemic, its easy to forget one of the largest health challenges we face remains the global obesity epidemic. World Health Organisation data shows obesity has nearly tripled in less than 50 years, with about 40 per cent of adults worldwide now overweight or obese. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast Continue reading →